Application note: Determining the structure of impurities
Most, if not all pharmaceutical companies will have experienced a product, that has been on the market for a long time, to suddenly and unexpectedly trigger a signal for an unknown substance in the quality control (QC) laboratory approval process.
Deciding on the next course of action is of the upmost importance to the company’s success. Ultimately, the most important consideration is product quality and safety, however the financial impact is also a commercial priority too.
Related content from this organisation
- Technical bulletin: An updated approach to E&L testing per ISO 10993-18:2020
- Technical bulletin: Nitrosamines: Questioning the current analytical approach
- Quality driven solutions from discovery to commercialisation
- SGS experts help to mitigate the risk of nitrosamine impurities in drug products
- Guide to Outsourcing